Correlation between HER-2/neu(erbB-2) expression level and therapeutic effect of combination treatment with HERCEPTIN and chemotherapeutic agents in gastric cancer cell lines

Cancer Cell International

Volumn 14, Issue 1, 2014, Pages

  Cui, Hai ^a   Cheng, Ying ^b   Piao, Su Zhou ^a   Xu, Yun Jie ^a   Sun, Hong Hua ^a   Cui, Xian ^a   Li, Xiang Zi ^a   Zhang, Song Nan ^a   Piao, Long Zhen ^a   Jin, Yong Min ^a   Lin, Zhen hua ^a   Shen, Xiong Hu ^a  

^a YANBIAN UNIVERSITY   (China)

^b JILIN CANCER HOSPITAL   (China)

Author keywords

CI; Combination treatment; Gastric cancer; HER 2 neu(erbB 2); HERCEPTIN

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; PACLITAXEL; TRASTUZUMAB;

ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOTOXICITY TEST; DRUG CYTOTOXICITY; EVALUATION STUDY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MTT ASSAY; PROTEIN EXPRESSION; STOMACH CANCER; THERAPY EFFECT;

EID: 84892952578     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-14-10     Document Type: Article

References (35)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2(2):127-137.
2. Cross M, Dexter TM. Growth factors in development, transformation, and tumorigenesis. Cell 1991, 64(2):271-280.
3. Tal M, Wetzler M, Josefberg Z, Deutch A, Gutman M, Assaf D, Kris R, Shiloh Y, Givol D, Schlessinger J. Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues. Cancer Res 1988, 48(6):1517-1520.
4. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985, 229(4717):974-976.
5. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244(4905):707-712.
6. Reese DM, Slamon DJ. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells 1997, 15(1):1-8.
7. Hung MC, Lau YK. Basic science of HER-2/neu: a review. Semin Oncol 1999, 26(4 Suppl 12):51-59.
8. Sahin AA. Biologic and clinical significance of HER-2/neu (cerbB-2) in breast cancer. Adv Anat Pathol 2000, 7(3):158-166.
9. Doss S, Robertson J, Adam J. Lapatinib or trastuzumab in combination with an aromatase inhibitor for first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2. Lancet Oncol 2012, 13(8):766-767.
10. McCaughan H, Um I, Langdon SP, Harrison DJ, Faratian D. HER2 expression in ovarian carcinoma: caution and complexity in biomarker analysis. J Clin Pathol 2012, 65(7):670-671. author reply 671-672.
11. Yan B, Choo SN, Mulyadi P, Srivastava S, Ong CW, Yong KJ, Putti T, Salto-Tellez M, Lim GS. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours. J Clin Pathol 2011, 64(12):1097-1101.
12. Dai GH, Shi Y, Chen L, Lv YL, Zhong M. Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression. Hepatogastroenterology 2012, 59(120):2439-2444.
13. Liu AN, Sun P, Liu JN, Ma JB, Qu HJ, Zhu H, Yu CY, Zhang LM. Clinicopathologic characteristics and prognostic factors in patients with operable HER-2 overexpressing breast cancer. Asian Pac J Cancer Prev 2012, 13(4):1197-1201.
14. Steffensen KD, Waldstrom M, Brandslund I, Jakobsen A. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients. Int J Gynecol Cancer 2011, 21(6):1040-1047.
15. Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jager E, Altmannsberger HM, Robinson E, Tafe LJ, Tang LH, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol 2012, 23(10):2656-2662.
16. Ignatoski KM, Maehama T, Markwart SM, Dixon JE, Livant DL, Ethier SP. ERBB-2 overexpression confers PI 3′ kinase-dependent invasion capacity on human mammary epithelial cells. Br J Cancer 2000, 82(3):666-674.
17. Hashimoto K, Yamamoto H, Shiratsuchi H, Nakashima T, Tamiya S, Nishiyama K, Higaki Y, Komune S, Tsuneyoshi M, Oda Y. HER-2/neu gene amplification in carcinoma ex pleomorphic adenoma in relation to progression and prognosis: a chromogenic in-situ hybridization study. Histopathology 2012, 60(6B):E131-E142.
18. Zhang YF, Guan YB, Yang B, Wu HY, Dai YT, Zhang SJ, Wang JP, Anoopkumar-Dukie S, Davey AK, Sun ZY. Prognostic value of Her-2/neu and clinicopathologic factors for evaluating progression and disease-specific death in Chinese men with prostate cancer. Chin Med J (Engl) 2011, 124(24):4345-4349.
19. Renner C, Zemitzsch N, Fuchs B, Geiger KD, Hermes M, Hengstler J, Gebhardt R, Meixensberger J, Gaunitz F. Carnosine retards tumor growth in vivo in an NIH3T3-HER2/neu mouse model. Mol Cancer 2010, 9:2.
20. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999, 18(13):2241-2251.
21. Yan SY, Hu Y, Fan JG, Tao GQ, Lu YM, Cai X, Yu BH, Du YQ. Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma. World J Gastroenterol 2011, 17(11):1501-1506.
22. Wang S, Zheng G, Chen L, Xiong B. Effect of HER-2/neu over-expression on prognosis in gastric cancer: a meta-analysis. Asian Pac J Cancer Prev 2011, 12(6):1417-1423.
23. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999, 26(4 Suppl 12):60-70.
24. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 1999, 26(4 Suppl 12):78-83.
25. Pegram MD, Slamon DJ. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin Oncol 1999, 26(4 Suppl 12):89-95.
26. Revillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998, 34(6):791-808.
27. Wang SL, Li YX, Song YW, Wang WH, Jin J, Liu YP, Liu XF, Yu ZH. Triple-negative or HER2-positive status predicts higher rates of locoregional recurrence in node-positive breast cancer patients after mastectomy. Int J Radiat Oncol Biol Phys 2011, 80(4):1095-1101.
28. Ren H, Li J, Liu JJ, Guo HL, Jiang T. Anti-HER-2 anti-CD3 Bi-specific Antibodies Inhibit Growth of HCT-116 Colorectal Carcinoma Cells in Vitro and in Vivo. Asian Pac J Cancer Prev 2012, 13(6):2795-2798.
29. Plowman GD, Culouscou JM, Whitney GS, Green JM, Carlton GW, Foy L, Neubauer MG, Shoyab M. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 1993, 90(5):1746-1750.
30. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344(11):783-792.
31. Chang YF, Li LL, Wu CW, Liu TY, Lui WY, P'Eng FK, Chi CW. Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Cancer 1996, 77(1):14-18.
32. Baselga J, Seidman AD, Rosen PP, Norton L. HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology (Williston Park) 1997, 11(3 Suppl 2):43-48.
33. Yu D, Liu B, Tan M, Li J, Wang SS, Hung MC. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 1996, 13(6):1359-1365.
34. Costantini DL, Villani DF, Vallis KA, Reilly RM. Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab. J Nucl Med 2010, 51(3):477-483.
35. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994, 86(20):1517-1524.